Zim Laboratories amends Code of Fair Disclosure for UPSI, effective Jan 19, 2026
Zim Laboratories Limited amended its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). The amended code is effective from January 19, 2026. The company has updated its procedures for disclosing UPSI and will host the amended code on its website. Piyush Nikhade is the designated CIRO.
The amendment to the Code of Fair Disclosure is a procedural update and a compliance measure. It does not introduce any new business opportunities, financial changes, or operational impacts that would significantly affect the company's stakeholders or stock price in the short to medium term.
The announcement is a routine update regarding amendments to the company's internal code of conduct for fair disclosure of price-sensitive information, as required by SEBI regulations. It does not contain any new financial information or strategic developments that would impact the company's performance.
Zim Laboratories Limited has announced an amendment to its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). This amendment is effective from January 19, 2026.
The company has submitted a copy of the amended Code of Fair Disclosure to the BSE Limited and the National Stock Exchange of India Limited. The updated code will also be hosted on the official website of Zim Laboratories Limited, www.zimlab.in, for public access.
The amended code, as per SEBI (Prohibition of Insider Trading) Regulations, 2015, outlines practices and procedures for the prompt, uniform, and universal disclosure of UPSI. It emphasizes making credible and concrete information generally available as soon as it comes into being. The code also details the handling of UPSI on a need-to-know basis, responses to market rumors, and the management of information shared with analysts and research personnel. Furthermore, it establishes a structured digital database for recipients of UPSI and defines "legitimate purposes" for sharing such information, including during corporate actions, financial result preparations, and other business-related transactions. The Company Secretary and Compliance Officer, Piyush Nikhade, has been designated as the Chief Investor Relations Officer (CIRO) to oversee these disclosures.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under corporate governance report. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.